CA
NZ
UK
AU
IND
US
InMed Pharmaceuticals Inc. (NASDAQ: INM) saw ADAR1 Capital Management acquire roughly $117,700 in common stock through open-market transactions.
Nuvation Bio Inc. (NYSE: NUVB) secured FDA approval for a supplemental New Drug Application revising the label for IBTROZI, incorporating a 49.7-month median duration of response from the TRUST-I study in TKI-naive ROS1-positive non-small cell lung cancer.
Cue Biopharma, Inc. (NASDAQ: CUE) reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria, meeting all primary endpoints and its key secondary endpoint at 4 mg/kg with significant improvements over placebo and a favorable safety profile.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) regained compliance with Nasdaq's $1.00 minimum bid price requirement after trading at or above the threshold for 19 consecutive business days, formally closing the listing deficiency and removing the related near-term delisting overhang.
Alkermes plc (NASDAQ: ALKS) reported positive Phase 1b proof-of-concept data for ALKS 7290 in adults with ADHD, showing dose-dependent, clinically meaningful improvements in AISRS and CGI-S scores with generally favorable tolerability and no serious treatment-emergent adverse events.
Telix Pharmaceuticals Limited (NASDAQ: TLX) entered into an agreement to purchase ITM Isotope Technologies Munich, featuring $1.65 billion upfront alongside maximum milestone payouts of $700 million tied to ITM-11.
Precigen, Inc. (NASDAQ: PGEN) secured FDA Platform Technology Designation regarding its AdenoVerse gene therapy setup, a framework that supports PAPZIMEOS for recurrent respiratory papillomatosis and offers potential regulatory efficiencies for subsequent pipeline candidates through shared CMC and preclinical assets.
XORTX Therapeutics Inc. (NASDAQ: XRTX) shares closed up 16% at $1.92 after the company announced it intends to file an Investigational New Drug application for its gout asset XRx-026 in the fourth quarter of 2026.
Longeveron Inc. (NASDAQ: LGVN) shares closed down 8% at $2.49 after the company announced that its Phase 2b ELPIS II trial evaluating laromestrocel in hypoplastic left heart syndrome failed to meet the primary right ventricular ejection fraction endpoint, with secondary survival and MACE outcomes …
MediciNova, Inc. (NASDAQ: MNOV) received coverage initiation from Roth MKM with a Buy rating alongside a $6.00 price target, driven by enthusiasm for core small-molecule pipeline asset MN-166 (ibudilast) as it advances through Phase 3 testing in amyotrophic lateral sclerosis and degenerative cervical myelopathy.
Please wait processing your request...